Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M157Revenue $M0.1Net Margin (%)-52,307.0Altman Z-Score-3.3
Enterprise Value $M91.4EPS $-0.6Operating Margin %-55,180.0Piotroski F-Score4
P/E(ttm)--Beneish M-Score238Pre-tax Margin (%)-52,306.0Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %-11.5Quick Ratio3.2Cash flow > EarningsY
Price/Sales--5-y EBITDA Growth Rate %5.9Current Ratio3.2Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-54.9Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-69.0Less Shares Outstanding y-yY
Payout Ratio %--Shares Outstanding M55.7ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with CYTR

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
CYTRGeorge Soros 2014-06-30 Sold Out $2.92 - $5.31
($3.79)
$ 2.81-26%Sold Out0
CYTRGeorge Soros 2014-03-31 Buy $3.18 - $8.08
($5.96)
$ 2.81-53%New holding81,800
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

CYTR is held by these investors:

No Entry found in the selected group of Gurus. You can
Premium Most recent portfolio changes are included for Premium Members only!


CYTR: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Patterson Scott Bradford10% Owner 2013-12-03Buy284,979$2.4415.16 view
Patterson Scott Bradford10% Owner 2013-11-07Buy50,000$2.0636.41 view
Patterson Scott Bradford10% Owner 2013-04-01Buy4,083$2.74.07 view
Patterson Scott Bradford10% Owner 2013-03-20Buy35,520$2.588.91 view
Patterson Scott Bradford10% Owner 2013-03-20Buy3,980$2.617.66 view
Patterson Scott Bradford10% Owner 2013-03-13Buy55,360$2.675.24 view
Patterson Scott Bradford10% Owner 2012-10-22Buy180,000$2.5111.95 view
Patterson Scott Bradford10% Owner 2012-10-18Buy1,200,000$2.512.4 view
Patterson Scott Bradford10% Owner 2012-06-28Buy44,824$5.14-45.33 view
Patterson Scott Bradford10% Owner 2012-06-25Buy27,462$5-43.8 view

Quarterly/Annual Reports about CYTR:

News about CYTR:

Articles On GuruFocus.com
Weekly CFO Buys Highlight: CYTR, API, CLGX, PLBC, ARTC Mar 05 2012 
Weekly CEO Buys Highlight: ULBI, BDE, ALNY, CTTR, GFN Feb 27 2012 
Weekly CFO Buys Highlight: CYTR, PZZI, AGYS, PLBC Feb 27 2012 
CytRx Corp. Reports Operating Results (10-K) Mar 11 2011 
CytRx Corp. Reports Operating Results (10-Q) Nov 08 2010 
CytRx Corp. Reports Operating Results (10-Q) Aug 09 2010 
CytRx Corp. Reports Operating Results (10-Q) May 06 2010 
CytRx Corp. Reports Operating Results (10-Q) Nov 09 2009 
CytRx Reports 2009 Second Quarter Financial Results Aug 10 2009 
CytRx Corp. Reports Operating Results (10-Q) Aug 07 2009 

More From Other Websites
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters'... Jul 24 2015
CytRx Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters'... Jul 24 2015
The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts Jul 23 2015
CYTRX CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Jul 21 2015
CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock Jul 21 2015
CytRx Announces Pricing of Public Offering of 9.1 Million Shares of Common Stock Jul 21 2015
CytRx Announces Proposed Public Offering of Common Stock Jul 20 2015
CYTRX CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 20 2015
CytRx Announces Proposed Public Offering of Common Stock Jul 20 2015
CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform Jun 30 2015
CytRx Unveils Novel LADR™ (Linker Activated Drug Release) Technology Platform Jun 30 2015
CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's... Jun 29 2015
CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's... Jun 29 2015
CYTRX CORP Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Jun 24 2015
Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors Jun 24 2015
Cheryl Cohen, Former Medivation Chief Commercial Officer, Joins CytRx Board of Directors Jun 24 2015
CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware Jun 02 2015
CytRx Announces Settlement of Stockholder Derivative Lawsuit in Delaware Jun 02 2015
CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting May 27 2015
CytRx to Present Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting May 27 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK